Document is current
Any future updates will be listed below
-
Authors
Noble, Richard A.
Thomas, Huw
Zhao, Yan
Herendi, Lili
Howarth, Rachel
Dragoni, Ilaria
Keun, Hector C. https://orcid.org/0000-0001-7358-8851
Vellano, Christopher P.
Marszalek, Joseph R.
Wedge, Stephen R. https://orcid.org/0000-0002-3644-6157
-
Funding
Funding for this research was provided by:
Cancer Research UK (C17375/A19482, Drug Discovery Committee Specialist Unit Agreement)
- License Information
-
More Information
Article History
Received: 29 May 2021
Revised: 22 April 2022
Accepted: 6 May 2022
First Online: 26 May 2022
Competing interests
: SRW is a former employee and stockholder of AstraZeneca and receives research funding from Cancer Research UK and Astex Pharmaceuticals. ID is an employee of Cancer Research UK which acquired the development rights to AZD3965 from AstraZeneca. JRM and CPV are employees of the MD Anderson Cancer Centre which holds the patent on IACS-010759. RAN, HT, YZ and RH were funded by Cancer Research UK. No disclosures were reported by the other authors.
: This study did not involve human participants, human data or the acquisition of human tissue. All in vivo experiments conducted in mice were reviewed and approved by the relevant institutional animal welfare committees (Newcastle University Animal Welfare Ethical Review Board) and performed according to the Guidelines for the Welfare set out by an ad hoc committee of the National Cancer Research Institute (Workman et al. []) and national law (Animals (Scientific Procedures) Act (1986)).
: Not applicable to this study. All authors have reviewed the final version of the manuscript and consent to its publication.
